Header Logo

Connection

Michael Cookson to Humans

Back to Details
This is a "connection" page, showing publications Michael Cookson has written about Humans.
Michael Cookson
Connection Strength
2.516
Humans
  1. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II. J Urol. 2021 Jan; 205(1):22-29.
    View in: PubMed
    Score: 0.040
  2. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I. J Urol. 2021 Jan; 205(1):14-21.
    View in: PubMed
    Score: 0.040
  3. Editorial Comment. J Urol. 2020 05; 203(5):931-932.
    View in: PubMed
    Score: 0.038
  4. The changing landscape in the management of newly diagnosed castration sensitive metastatic prostate cancer. Investig Clin Urol. 2020 02; 61(Suppl 1):S3-S7.
    View in: PubMed
    Score: 0.038
  5. Urology perspective on the expanding world of germline testing for prostate cancer. Can J Urol. 2019 10; 26(5 Suppl 2):5-6.
    View in: PubMed
    Score: 0.038
  6. Recent trends in the management of advanced prostate cancer. F1000Res. 2018; 7.
    View in: PubMed
    Score: 0.035
  7. Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018. J Urol. 2018 12; 200(6):1264-1272.
    View in: PubMed
    Score: 0.035
  8. Editorial Comment. J Urol. 2018 08; 200(2):290-291.
    View in: PubMed
    Score: 0.034
  9. Urinary Diversion: Nutritional Evolution and Surgical Revolution. Urol Clin North Am. 2018 02; 45(1):xvii.
    View in: PubMed
    Score: 0.033
  10. Castration-Resistant Prostate Cancer: An Algorithmic Approach. Urol Clin North Am. 2017 Nov; 44(4):647-655.
    View in: PubMed
    Score: 0.033
  11. Clostridium difficile Infection in Contemporary Urologic Practice. Urology. 2018 Jan; 111:23-27.
    View in: PubMed
    Score: 0.032
  12. Salvage Surgery After Renal Mass Ablation. Urol Clin North Am. 2017 May; 44(2):305-312.
    View in: PubMed
    Score: 0.031
  13. Advances in the management of castration resistant prostate cancer. BMJ. 2016 Oct 17; 355:i4405.
    View in: PubMed
    Score: 0.031
  14. Radical Cystectomy-The Waiting is the Hardest Part…or is it? J Urol. 2016 04; 195(4 Pt 1):821-2.
    View in: PubMed
    Score: 0.029
  15. Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2015. J Urol. 2016 May; 195(5):1444-1452.
    View in: PubMed
    Score: 0.029
  16. Editorial Comment for Bolton et al. J Endourol. 2015 Jul; 29(7):850.
    View in: PubMed
    Score: 0.028
  17. Castration-resistant prostate cancer: AUA guideline amendment. J Urol. 2015 Feb; 193(2):491-9.
    View in: PubMed
    Score: 0.027
  18. Best evidence regarding the superiority or inferiority of robot-assisted radical prostatectomy. Urol Clin North Am. 2014 Nov; 41(4):493-502.
    View in: PubMed
    Score: 0.026
  19. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides. Eur Urol. 2015 Jan; 67(1):165-170.
    View in: PubMed
    Score: 0.025
  20. Prostate cancer: Could sensitive PSA assays expedite salvage radiotherapy? Nat Rev Urol. 2014 Jan; 11(1):14-5.
    View in: PubMed
    Score: 0.025
  21. Castration-resistant prostate cancer: AUA Guideline. J Urol. 2013 Aug; 190(2):429-38.
    View in: PubMed
    Score: 0.024
  22. Positive surgical margins at radical prostatectomy: much ado about nothing? Urol Oncol. 2013 Apr; 31(3):285-7.
    View in: PubMed
    Score: 0.024
  23. A 57-year-old man with a history of prostatectomy and pelvic irradiation presents with recurrent urinary tract infections, hematuria, and pelvic pain. Urology. 2013 Feb; 81(2):221-5.
    View in: PubMed
    Score: 0.024
  24. Surgical and chemotherapeutic management of regional lymph nodes in bladder cancer. J Urol. 2012 Oct; 188(4):1081-8.
    View in: PubMed
    Score: 0.023
  25. Lymph node yield at radical cystectomy predicts mortality in node-negative and not node-positive patients. Urology. 2012 Sep; 80(3):632-40.
    View in: PubMed
    Score: 0.023
  26. National practice patterns for immediate postoperative instillation of chemotherapy in nonmuscle invasive bladder cancer. J Urol. 2012 May; 187(5):1571-6.
    View in: PubMed
    Score: 0.022
  27. Inferior vena cava filter strut perforation discovered during right robotic-assisted laparoscopic partial nephrectomy. Urology. 2012 Apr; 79(4):e49-50.
    View in: PubMed
    Score: 0.022
  28. The relationship between perioperative blood transfusion and overall mortality in patients undergoing radical cystectomy for bladder cancer. Urol Oncol. 2013 Aug; 31(6):871-7.
    View in: PubMed
    Score: 0.021
  29. Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy. J Urol. 2011 Sep; 186(3):829-34.
    View in: PubMed
    Score: 0.021
  30. Complications of pelvic lymph node dissection for prostate cancer. Curr Urol Rep. 2011 Jun; 12(3):203-8.
    View in: PubMed
    Score: 0.021
  31. Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series. J Urol. 2010 Oct; 184(4):1296-300.
    View in: PubMed
    Score: 0.020
  32. Margin control in open radical prostatectomy: what are the real outcomes? Urol Oncol. 2010 Mar-Apr; 28(2):205-9.
    View in: PubMed
    Score: 0.019
  33. Should pelvic lymph node dissection be performed with radical prostatectomy? No. J Urol. 2010 Apr; 183(4):1284-5.
    View in: PubMed
    Score: 0.019
  34. Comparison of transfusion requirements between open and robotic-assisted laparoscopic radical prostatectomy. BJU Int. 2010 Oct; 106(7):1036-40.
    View in: PubMed
    Score: 0.019
  35. Overview of SUO Winter 2008 proceedings. Urol Oncol. 2010 Jan-Feb; 28(1):67-8.
    View in: PubMed
    Score: 0.019
  36. Open renal biopsy: comorbidities and complications in a contemporary series. BJU Int. 2010 Jul; 106(1):102-6.
    View in: PubMed
    Score: 0.019
  37. Urinary diversion trends at a high volume, single American tertiary care center. J Urol. 2009 Nov; 182(5):2369-74.
    View in: PubMed
    Score: 0.019
  38. Impact of surgeon and hospital volume on outcomes of radical prostatectomy. Urol Oncol. 2010 May-Jun; 28(3):243-50.
    View in: PubMed
    Score: 0.018
  39. Outcomes of patients undergoing radical cystoprostatectomy for bladder cancer with prostatic involvement on final pathology. BJU Int. 2009 Oct; 104(8):1091-7.
    View in: PubMed
    Score: 0.018
  40. The von Hippel-Lindau gene: turning discovery into therapy. Cancer. 2008 Oct 01; 113(7 Suppl):1768-78.
    View in: PubMed
    Score: 0.018
  41. A critical review of clinical practice guidelines for the management of clinically localized prostate cancer. J Urol. 2008 Aug; 180(2):451-9; discussion 460.
    View in: PubMed
    Score: 0.017
  42. Effect of a large prostate gland on open and robotically assisted laparoscopic radical prostatectomy. BJU Int. 2008 May; 101(9):1140-4.
    View in: PubMed
    Score: 0.017
  43. Contemporary open radical cystectomy: analysis of perioperative outcomes. J Urol. 2008 Apr; 179(4):1313-8; discussion 1318.
    View in: PubMed
    Score: 0.017
  44. A comparison of the incidence and location of positive surgical margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy. J Urol. 2007 Dec; 178(6):2385-9; discussion 2389-90.
    View in: PubMed
    Score: 0.016
  45. Urothelial carcinoma of the bladder metastatic to bone marrow presenting as isolated thrombocytopenia. ScientificWorldJournal. 2007 Jun 12; 7:1000-3.
    View in: PubMed
    Score: 0.016
  46. The evidence-based pathway for peri-operative management of open and robotically assisted laparoscopic radical prostatectomy. BJU Int. 2007 May; 99(5):1103-8.
    View in: PubMed
    Score: 0.016
  47. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007 Feb; 177(2):540-5.
    View in: PubMed
    Score: 0.016
  48. Impact of positive surgical margins after radical prostatectomy. Urology. 2006 Aug; 68(2):249-52.
    View in: PubMed
    Score: 0.015
  49. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer. BJU Int. 2006 Jun; 97(6):1169-72.
    View in: PubMed
    Score: 0.015
  50. Mechanisms leading to the development of hormone-resistant prostate cancer. Urol Clin North Am. 2006 May; 33(2):201-10, vii.
    View in: PubMed
    Score: 0.015
  51. Positive influence of robotically assisted laparoscopic prostatectomy on the collaborative-care pathway for open radical prostatectomy. BJU Int. 2006 Mar; 97(3):473-5.
    View in: PubMed
    Score: 0.015
  52. Non-muscle-invasive bladder cancer: the role of radical cystectomy. Urology. 2005 Nov; 66(5):917-22.
    View in: PubMed
    Score: 0.014
  53. Safely reducing length of stay after open radical retropubic prostatectomy under the guidance of a clinical care pathway. Cancer. 2005 Aug 15; 104(4):747-51.
    View in: PubMed
    Score: 0.014
  54. Performance-enhancing supplement use in patients with testicular cancer. Urology. 2005 Aug; 66(2):242-5.
    View in: PubMed
    Score: 0.014
  55. Radical cystectomy for bladder cancer: the case for early intervention. Urol Clin North Am. 2005 May; 32(2):147-55.
    View in: PubMed
    Score: 0.014
  56. The surgical management of muscle invasive bladder cancer: a contemporary review. Semin Radiat Oncol. 2005 Jan; 15(1):10-8.
    View in: PubMed
    Score: 0.013
  57. A pilot randomized clinical trial of a smartphone-based application to support at-home PSA screening and culturally tailored prostate cancer education for African American men: A study protocol. Contemp Clin Trials. 2024 Dec; 147:107737.
    View in: PubMed
    Score: 0.013
  58. Ileal conduit urinary diversion in patients with previous history of abdominal/pelvic irradiation. World J Urol. 2004 Oct; 22(4):272-6.
    View in: PubMed
    Score: 0.013
  59. Surgical complications of urinary diversion. World J Urol. 2004 Sep; 22(3):157-67.
    View in: PubMed
    Score: 0.013
  60. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Gu?rin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol. 2024 Jul; 212(1):74-86.
    View in: PubMed
    Score: 0.013
  61. Predicting blood loss and transfusion requirements during radical prostatectomy: the significant negative impact of increasing body mass index. J Urol. 2004 May; 171(5):1861-5.
    View in: PubMed
    Score: 0.013
  62. Increased body mass index predicts increased blood loss during radical cystectomy. J Urol. 2004 Mar; 171(3):1077-9.
    View in: PubMed
    Score: 0.013
  63. Complications of contemporary radical nephrectomy: comparison of open vs. laparoscopic approach. Urol Oncol. 2004 Mar-Apr; 22(2):121-6.
    View in: PubMed
    Score: 0.013
  64. Advances in diagnosis and treatment of bladder cancer. BMJ. 2024 02 12; 384:e076743.
    View in: PubMed
    Score: 0.013
  65. Primary renal carcinoid tumor. J Urol. 2004 Jan; 171(1):338.
    View in: PubMed
    Score: 0.013
  66. Health related quality of life in patients treated with radical cystectomy and urinary diversion for urothelial carcinoma of the bladder: development and validation of a new disease specific questionnaire. J Urol. 2003 Nov; 170(5):1926-30.
    View in: PubMed
    Score: 0.012
  67. Decreasing blood loss in patients treated with radical cystectomy: a prospective randomizes trial using a new stapling device. J Urol. 2003 Mar; 169(3):951-4.
    View in: PubMed
    Score: 0.012
  68. Impact of Maximal Transurethral Resection on Pathological Outcomes at Cystectomy in a Large, Multi-institutional Cohort. J Urol. 2023 05; 209(5):882-889.
    View in: PubMed
    Score: 0.012
  69. Complications of radical cystectomy for nonmuscle invasive disease: comparison with muscle invasive disease. J Urol. 2003 Jan; 169(1):101-4.
    View in: PubMed
    Score: 0.012
  70. Multicenter evaluation of neoadjuvant and induction gemcitabine-carboplatin versus gemcitabine-cisplatin followed by radical cystectomy for muscle-invasive bladder cancer. World J Urol. 2022 Nov; 40(11):2707-2715.
    View in: PubMed
    Score: 0.012
  71. The free/total prostate-specific antigen ratio (%fPSA) is the best predictor of tumor involvement in the radical prostatectomy specimen among men with an elevated PSA. Urol Oncol. 2002 Sep-Oct; 7(5):195-8.
    View in: PubMed
    Score: 0.011
  72. Beneficial impact of a clinical care pathway in patients with testicular cancer undergoing retroperitoneal lymph node dissection. J Urol. 2002 Jul; 168(1):87-92.
    View in: PubMed
    Score: 0.011
  73. Pathological findings of gynecologic organs obtained at female radical cystectomy. J Urol. 2002 Jul; 168(1):147-9.
    View in: PubMed
    Score: 0.011
  74. Health related quality of life assessment after radical cystectomy: comparison of ileal conduit with continent orthotopic neobladder. J Urol. 2002 Jul; 168(1):164-7.
    View in: PubMed
    Score: 0.011
  75. Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. Eur Urol Oncol. 2022 Oct; 5(5):505-516.
    View in: PubMed
    Score: 0.011
  76. Percent of cancer in the biopsy set predicts pathological findings after prostatectomy. J Urol. 2002 May; 167(5):2032-5; discussion 2036.
    View in: PubMed
    Score: 0.011
  77. Eosinophilic cystitis presenting as a recurrent symptomatic bladder mass following intravesical mitomycin C therapy. J Urol. 2002 Apr; 167(4):1795.
    View in: PubMed
    Score: 0.011
  78. Carcinoma in situ and tumor multifocality predict the risk of prostatic urethral involvement at radical cystectomy in men with transitional cell carcinoma of the bladder. J Urol. 2002 Feb; 167(2 Pt 1):502-5.
    View in: PubMed
    Score: 0.011
  79. Lymphoma presenting as a solitary renal hilar mass. Urology. 2002 Jan; 59(1):134-5.
    View in: PubMed
    Score: 0.011
  80. Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. Eur Urol. 2022 03; 81(3):223-228.
    View in: PubMed
    Score: 0.011
  81. Estimated blood loss and transfusion requirements of radical cystectomy. J Urol. 2001 Dec; 166(6):2151-4.
    View in: PubMed
    Score: 0.011
  82. Intrarectal lidocaine during transrectal prostate biopsy: results of a prospective double-blind randomized trial. J Urol. 2001 Dec; 166(6):2178-80.
    View in: PubMed
    Score: 0.011
  83. Health related quality of life assessment after radical prostatectomy in men with prostate specific antigen only recurrence. J Urol. 2001 Dec; 166(6):2286-90.
    View in: PubMed
    Score: 0.011
  84. Prediction of tumour volume and pathological stage in radical prostatectomy specimens is not improved by taking more prostate needle-biopsy cores. BJU Int. 2001 Nov; 88(7):722-6.
    View in: PubMed
    Score: 0.011
  85. Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer. J Urol. 2022 01; 207(1):70-76.
    View in: PubMed
    Score: 0.011
  86. Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. World J Urol. 2021 Dec; 39(12):4345-4354.
    View in: PubMed
    Score: 0.011
  87. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol. 2001 Aug; 166(2):490-3.
    View in: PubMed
    Score: 0.011
  88. The Growth of Integrated Care Models in Urology. Urol Clin North Am. 2021 May; 48(2):223-232.
    View in: PubMed
    Score: 0.010
  89. Ratio of free-to-total prostate specific antigen correlates with tumor volume in patients with increased prostate specific antigen. J Urol. 2001 Feb; 165(2):455-8.
    View in: PubMed
    Score: 0.010
  90. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021 01; 22(1):107-117.
    View in: PubMed
    Score: 0.010
  91. Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis. BJU Int. 2021 07; 128(1):79-87.
    View in: PubMed
    Score: 0.010
  92. Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. BJU Int. 2021 05; 127(5):528-537.
    View in: PubMed
    Score: 0.010
  93. Nomogram Predicting Bladder Cancer-specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium. Eur Urol Focus. 2021 Nov; 7(6):1347-1354.
    View in: PubMed
    Score: 0.010
  94. Large-scale pathway specific polygenic risk and transcriptomic community network analysis identifies novel functional pathways in Parkinson disease. Acta Neuropathol. 2020 09; 140(3):341-358.
    View in: PubMed
    Score: 0.010
  95. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol. 2020 08 20; 38(24):2798-2811.
    View in: PubMed
    Score: 0.010
  96. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med. 2020 06 04; 382(23):2187-2196.
    View in: PubMed
    Score: 0.010
  97. 8q24 genetic variation and comprehensive haplotypes altering familial risk of prostate cancer. Nat Commun. 2020 03 23; 11(1):1523.
    View in: PubMed
    Score: 0.010
  98. Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines. Prostate. 2020 05; 80(6):527-544.
    View in: PubMed
    Score: 0.010
  99. Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. Urol Oncol. 2020 07; 38(7):639.e1-639.e9.
    View in: PubMed
    Score: 0.010
  100. Update on transrectal ultrasound-guided needle biopsy of the prostate. Mol Urol. 2000; 4(3):93-7; discussion 99.
    View in: PubMed
    Score: 0.010
  101. The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. Urol Oncol. 2020 01; 38(1):3.e17-3.e27.
    View in: PubMed
    Score: 0.009
  102. Predictors of Recurrence, and Progression-Free and Overall Survival following Open versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year Followup. J Urol. 2020 03; 203(3):522-529.
    View in: PubMed
    Score: 0.009
  103. Reply by Authors. J Urol. 2019 10; 202(4):820.
    View in: PubMed
    Score: 0.009
  104. Bilateral ureteritis cystica with unilateral ureteropelvic junction obstruction. Tech Urol. 1999 Jun; 5(2):108-12.
    View in: PubMed
    Score: 0.009
  105. Perioperative Oral Nutrition Supplementation Reduces Prevalence of Sarcopenia following Radical Cystectomy: Results of a Prospective Randomized Controlled Trial. J Urol. 2019 03; 201(3):470-477.
    View in: PubMed
    Score: 0.009
  106. Risk of Ovarian Malignancy in Patients Undergoing Radical Cystectomy for Bladder Cancer. Urology. 2019 Jan; 123:181-185.
    View in: PubMed
    Score: 0.009
  107. Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD-SIU joint consultation on bladder cancer. World J Urol. 2019 Jan; 37(1):3-13.
    View in: PubMed
    Score: 0.009
  108. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet. 2018 06 23; 391(10139):2525-2536.
    View in: PubMed
    Score: 0.009
  109. Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy. World J Urol. 2019 Jan; 37(1):165-172.
    View in: PubMed
    Score: 0.009
  110. Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review. Eur Urol Oncol. 2018 08; 1(3):223-230.
    View in: PubMed
    Score: 0.009
  111. Robotic Cystectomy with Intracorporeal Urinary Diversion: Review of Current Techniques and Outcomes. Urol Clin North Am. 2018 Feb; 45(1):67-77.
    View in: PubMed
    Score: 0.008
  112. Transition from androgenic to neurosteroidal action of 5a-androstane-3a, 17ß-diol through the type A ?-aminobutyric acid receptor in prostate cancer progression. J Steroid Biochem Mol Biol. 2018 04; 178:89-98.
    View in: PubMed
    Score: 0.008
  113. Effects of primary care physician density, urologist presence, and insurance status on stage of diagnosis for urologic malignancies. Cancer Epidemiol. 2018 02; 52:10-14.
    View in: PubMed
    Score: 0.008
  114. Improving the quality of operative reports for transurethral resection of bladder tumor surgery in resident education. Can J Urol. 2017 Oct; 24(5):8976-8981.
    View in: PubMed
    Score: 0.008
  115. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol. 1997 Jul; 158(1):62-7.
    View in: PubMed
    Score: 0.008
  116. Prognostic significance of prostate-specific antigen in stage T1c prostate cancer treated by radical prostatectomy. Urology. 1997 Jun; 49(6):887-93.
    View in: PubMed
    Score: 0.008
  117. Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study. Br J Urol. 1997 Mar; 79(3):432-8.
    View in: PubMed
    Score: 0.008
  118. Minimally Invasive Versus Open Approach for Cystectomy: Trends in the Utilization and Demographic or Clinical Predictors Using the National Cancer Database. Urology. 2017 May; 103:99-105.
    View in: PubMed
    Score: 0.008
  119. Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. J Urol. 1997 Feb; 157(2):559-62.
    View in: PubMed
    Score: 0.008
  120. Glutathione S-transferase PI (GST-pi) class expression by immunohistochemistry in benign and malignant prostate tissue. J Urol. 1997 Feb; 157(2):673-6.
    View in: PubMed
    Score: 0.008
  121. TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma. Urol Oncol. 2017 05; 35(5):286-293.
    View in: PubMed
    Score: 0.008
  122. Oncologic Outcomes after Anterior Exenteration for Muscle Invasive Bladder Cancer in Women. J Urol. 2016 Oct; 196(4):1030-5.
    View in: PubMed
    Score: 0.007
  123. A 10-Item Checklist Improves Reporting of Critical Procedural Elements during Transurethral Resection of Bladder Tumor. J Urol. 2016 Oct; 196(4):1014-20.
    View in: PubMed
    Score: 0.007
  124. Short term complications from transurethral resection of bladder tumor. Can J Urol. 2016 Apr; 23(2):8198-203.
    View in: PubMed
    Score: 0.007
  125. The Evolving Biology of Castration-Resistant Prostate Cancer: Review of Recommendations From the Prostate Cancer Clinical Trials Working Group 3. Oncology (Williston Park). 2016 Feb; 30(2):187-95, 199.
    View in: PubMed
    Score: 0.007
  126. The lack of predictive value of prostate specific antigen density in the detection of prostate cancer in patients with normal rectal examinations and intermediate prostate specific antigen levels. J Urol. 1995 Sep; 154(3):1070-3.
    View in: PubMed
    Score: 0.007
  127. Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer. Am J Pathol. 2015 May; 185(5):1385-95.
    View in: PubMed
    Score: 0.007
  128. Can semen analysis predict the presence of antisperm antibodies in patients with primary infertility? World J Urol. 1995; 13(5):318-22.
    View in: PubMed
    Score: 0.007
  129. Korean version of the functional assessment of cancer therapy (FACT)-vanderbilt cystectomy index (VCI): translation and linguistic. Urol J. 2014 Nov 30; 11(6):1961-7.
    View in: PubMed
    Score: 0.007
  130. Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review. Eur Urol. 2015 May; 67(5):876-88.
    View in: PubMed
    Score: 0.007
  131. Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma. Urol Oncol. 2015 Jan; 33(1):21.e11-21.e17.
    View in: PubMed
    Score: 0.007
  132. Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. Nat Rev Urol. 2014 Oct; 11(10):589-96.
    View in: PubMed
    Score: 0.007
  133. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2015 Feb; 67(2):241-9.
    View in: PubMed
    Score: 0.007
  134. Impact of complications and hospital-free days on health related quality of life 1 year after radical cystectomy. J Urol. 2014 Nov; 192(5):1360-4.
    View in: PubMed
    Score: 0.006
  135. Biochemical recurrence-free survival after robotic-assisted laparoscopic vs open radical prostatectomy for intermediate- and high-risk prostate cancer. Urology. 2014 Jun; 83(6):1309-15.
    View in: PubMed
    Score: 0.006
  136. Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy. BJU Int. 2014 Jun; 113(6):894-9.
    View in: PubMed
    Score: 0.006
  137. An expressed retrogene of the master embryonic stem cell gene POU5F1 is associated with prostate cancer susceptibility. Am J Hum Genet. 2014 Mar 06; 94(3):395-404.
    View in: PubMed
    Score: 0.006
  138. Hormonal therapy for metastatic prostate cancer: issues of timing and total androgen ablation. South Med J. 1994 Jan; 87(1):1-6.
    View in: PubMed
    Score: 0.006
  139. Racial variation in the quality of surgical care for bladder cancer. Cancer. 2014 Apr 01; 120(7):1018-25.
    View in: PubMed
    Score: 0.006
  140. Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database. Urology. 2014 Jan; 83(1):75-80.
    View in: PubMed
    Score: 0.006
  141. Blood loss associated with radical cystectomy: a prospective, randomized study comparing Impact LigaSure vs. stapling device. Urol Oncol. 2014 Jan; 32(1):45.e11-5.
    View in: PubMed
    Score: 0.006
  142. Locoregional small cell carcinoma of the bladder: clinical characteristics and treatment patterns. J Urol. 2014 Feb; 191(2):329-34.
    View in: PubMed
    Score: 0.006
  143. Utilizing E-coded data for nonfatal injury surveillance in the pediatric emergency department setting: a literature review and recommendations. Pediatr Emerg Care. 2013 Jul; 29(7):801-5.
    View in: PubMed
    Score: 0.006
  144. Analysis of microsurgical penile revascularization results by etiology of impotence. J Urol. 1993 May; 149(5 Pt 2):1308-12.
    View in: PubMed
    Score: 0.006
  145. Challenges in the pathology of non-muscle-invasive bladder cancer: a dialogue between the urologic surgeon and the pathologist. Urology. 2013 Jun; 81(6):1123-30.
    View in: PubMed
    Score: 0.006
  146. Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. J Urol. 2013 Jun; 189(6):2039-46.
    View in: PubMed
    Score: 0.006
  147. Long-term results with vacuum constriction device. J Urol. 1993 Feb; 149(2):290-4.
    View in: PubMed
    Score: 0.006
  148. Screening for bladder cancer: rationale, limitations, whom to target, and perspectives. Eur Urol. 2013 Jun; 63(6):1049-58.
    View in: PubMed
    Score: 0.006
  149. Ureteroenteric anastomotic strictures after radical cystectomy-does operative approach matter? J Urol. 2013 Feb; 189(2):541-7.
    View in: PubMed
    Score: 0.006
  150. Volume outcomes of cystectomy--is it the surgeon or the setting? J Urol. 2012 Dec; 188(6):2139-44.
    View in: PubMed
    Score: 0.006
  151. Salvage robotic assisted laparoscopic radical prostatectomy: a single institution, 5-year experience. J Urol. 2013 Feb; 189(2):507-13.
    View in: PubMed
    Score: 0.006
  152. ABO blood group is a predictor of survival in patients undergoing surgery for renal cell carcinoma. BJU Int. 2012 Dec; 110(11 Pt B):E641-6.
    View in: PubMed
    Score: 0.006
  153. Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. J Urol. 1992 Sep; 148(3):797-801.
    View in: PubMed
    Score: 0.006
  154. Racial variation in the quality of surgical care for prostate cancer. J Urol. 2012 Oct; 188(4):1279-85.
    View in: PubMed
    Score: 0.006
  155. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013 Jan; 63(1):45-57.
    View in: PubMed
    Score: 0.006
  156. Psychometric characteristics of a condition-specific, health-related quality-of-life survey: the FACT-Vanderbilt Cystectomy Index. Urology. 2012 Jul; 80(1):77-83.
    View in: PubMed
    Score: 0.006
  157. Voiding function in women with orthotopic neobladder urinary diversion. J Urol. 2012 Jul; 188(1):200-4.
    View in: PubMed
    Score: 0.006
  158. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. PLoS One. 2012; 7(5):e36669.
    View in: PubMed
    Score: 0.006
  159. Recovery of urinary function after radical prostatectomy: identification of trajectory cluster groups. J Urol. 2012 Apr; 187(4):1346-51.
    View in: PubMed
    Score: 0.006
  160. National trends in the use of partial nephrectomy: a rising tide that has not lifted all boats. J Urol. 2012 Mar; 187(3):816-21.
    View in: PubMed
    Score: 0.005
  161. Spurious elevation of serum PSA after curative treatment for prostate cancer: clinical consequences and the role of heterophilic antibodies. Prostate Cancer Prostatic Dis. 2012 Jun; 15(2):182-8.
    View in: PubMed
    Score: 0.005
  162. Prostate size as a predictor of Gleason score upgrading in patients with low risk prostate cancer. J Urol. 2011 Dec; 186(6):2221-7.
    View in: PubMed
    Score: 0.005
  163. Tumour size, tumour complexity, and surgical approach are associated with nephrectomy type in small renal cortical tumours treated electively. BJU Int. 2012 Jun; 109(11):1607-13.
    View in: PubMed
    Score: 0.005
  164. Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer. BJU Int. 2012 Jan; 109(2):226-32.
    View in: PubMed
    Score: 0.005
  165. Urinary collecting system invasion is a predictor for overall and disease-specific survival in locally invasive renal cell carcinoma. Urology. 2011 Jul; 78(1):99-104.
    View in: PubMed
    Score: 0.005
  166. Oxidative stress measured by urine F2-isoprostane level is associated with prostate cancer. J Urol. 2011 Jun; 185(6):2102-7.
    View in: PubMed
    Score: 0.005
  167. Routine use of nasogastric tubes after radical cystectomy. J Urol. 2011 May; 185(5):1568-70.
    View in: PubMed
    Score: 0.005
  168. Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma. Eur Urol. 2011 Jun; 59(6):923-8.
    View in: PubMed
    Score: 0.005
  169. The associations between statin use and prostate cancer screening, prostate size, high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer. Cancer Causes Control. 2011 Mar; 22(3):417-26.
    View in: PubMed
    Score: 0.005
  170. Tumor volume as a predictor of adverse pathologic features and biochemical recurrence (BCR) in radical prostatectomy specimens: a tale of two methods. World J Urol. 2011 Feb; 29(1):15-20.
    View in: PubMed
    Score: 0.005
  171. Determining factors for hospital discharge status after radical cystectomy in a large contemporary cohort. J Urol. 2011 Jan; 185(1):85-9.
    View in: PubMed
    Score: 0.005
  172. Effect of preoperative nutritional deficiency on mortality after radical cystectomy for bladder cancer. J Urol. 2011 Jan; 185(1):90-6.
    View in: PubMed
    Score: 0.005
  173. Smaller prostate size predicts high grade prostate cancer at final pathology. J Urol. 2010 Sep; 184(3):930-7.
    View in: PubMed
    Score: 0.005
  174. Comparative analysis of whole mount processing and systematic sampling of radical prostatectomy specimens: pathological outcomes and risk of biochemical recurrence. J Urol. 2010 Oct; 184(4):1334-40.
    View in: PubMed
    Score: 0.005
  175. Preoperative hydronephrosis predicts extravesical and node positive disease in patients undergoing cystectomy for bladder cancer. J Urol. 2010 May; 183(5):1732-7.
    View in: PubMed
    Score: 0.005
  176. NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw. 2010 Feb; 8(2):240-62.
    View in: PubMed
    Score: 0.005
  177. Robotic assisted laparoscopic prostatectomy versus radical retropubic prostatectomy for clinically localized prostate cancer: comparison of short-term biochemical recurrence-free survival. J Urol. 2010 Mar; 183(3):990-6.
    View in: PubMed
    Score: 0.005
  178. Impact of positive apical surgical margins on likelihood of biochemical recurrence after radical prostatectomy. J Urol. 2009 Dec; 182(6):2695-701.
    View in: PubMed
    Score: 0.005
  179. Pathological stage T2 subgroups to predict biochemical recurrence after prostatectomy. J Urol. 2009 Nov; 182(5):2291-5.
    View in: PubMed
    Score: 0.005
  180. Immediate surgical outcomes for radical prostatectomy in the University HealthSystem Consortium Clinical Data Base: the impact of hospital case volume, hospital size and geographical region on 48,000 patients. BJU Int. 2009 Nov; 104(10):1442-5.
    View in: PubMed
    Score: 0.005
  181. Radical nephrectomy surgical outcomes in the University HealthSystem Consortium Data Base: Impact of hospital case volume, hospital size, and geographic location on 40,000 patients. Cancer. 2009 Jun 01; 115(11):2447-52.
    View in: PubMed
    Score: 0.005
  182. Risk factors for urothelial carcinoma of the prostate in patients undergoing radical cystoprostatectomy for bladder cancer. BJU Int. 2009 Oct; 104(7):934-7.
    View in: PubMed
    Score: 0.005
  183. Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume. J Urol. 2009 May; 181(5):2064-70.
    View in: PubMed
    Score: 0.005
  184. Primary endoscopic management versus open revision of ureteroenteric anastomotic strictures after urinary diversion--single institution contemporary series. J Endourol. 2009 Mar; 23(3):551-5.
    View in: PubMed
    Score: 0.005
  185. Comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial carcinoma: analysis of patient outcomes. Cancer. 2009 Feb 15; 115(4):770-5.
    View in: PubMed
    Score: 0.004
  186. Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer. J Urol. 2009 Feb; 181(2):540-5; discussion 546.
    View in: PubMed
    Score: 0.004
  187. Prognostic factors in T3b renal cell carcinoma. World J Urol. 2009 Feb; 27(1):75-9.
    View in: PubMed
    Score: 0.004
  188. Waiting time from initial urological consultation to nephrectomy for renal cell carcinoma--does it affect survival? J Urol. 2008 Jun; 179(6):2152-7.
    View in: PubMed
    Score: 0.004
  189. Neovesical-urethral anastomotic stricture after orthotopic urinary diversion: presentation and management. BJU Int. 2008 Jan; 101(2):219-22.
    View in: PubMed
    Score: 0.004
  190. Association between prostate-specific antigen and leptin, adiponectin, HbA1c or C-peptide among African-American and Caucasian men. Prostate Cancer Prostatic Dis. 2008; 11(3):264-9.
    View in: PubMed
    Score: 0.004
  191. Association of procedure volume with radical cystectomy outcomes in a nationwide database. J Urol. 2007 Oct; 178(4 Pt 1):1418-21; discussion 1421-2.
    View in: PubMed
    Score: 0.004
  192. Second prize: frequency of benign renal cortical tumors and histologic subtypes based on size in a contemporary series: what to tell our patients. J Endourol. 2007 Aug; 21(8):819-23.
    View in: PubMed
    Score: 0.004
  193. Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol. 2007 Aug; 178(2):597-601.
    View in: PubMed
    Score: 0.004
  194. Assessing retroperitoneal lymphadenectomy experience in United States urological residency programs. J Urol. 2007 Aug; 178(2):500-3; discussion 503.
    View in: PubMed
    Score: 0.004
  195. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007 Jun; 177(6):2106-31.
    View in: PubMed
    Score: 0.004
  196. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp Clin Trials. 2007 Nov; 28(6):763-9.
    View in: PubMed
    Score: 0.004
  197. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol. 2007 Jul; 178(1):68-73; discussion 73.
    View in: PubMed
    Score: 0.004
  198. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol. 2007 May; 177(5):1777-81.
    View in: PubMed
    Score: 0.004
  199. Comparison of length of hospital stay between radical retropubic prostatectomy and robotic assisted laparoscopic prostatectomy. J Urol. 2007 Mar; 177(3):929-31.
    View in: PubMed
    Score: 0.004
  200. Prostate volume modifies the association between obesity and prostate cancer or high-grade prostatic intraepithelial neoplasia. Cancer Causes Control. 2007 May; 18(4):375-84.
    View in: PubMed
    Score: 0.004
  201. Urothelial carcinoma of the prostate. Urology. 2007 Jan; 69(1 Suppl):50-61.
    View in: PubMed
    Score: 0.004
  202. The association between body size, prostate volume and prostate-specific antigen. Prostate Cancer Prostatic Dis. 2007; 10(2):137-42.
    View in: PubMed
    Score: 0.004
  203. Toxicity following high-dose salvage radiotherapy after radical prostatectomy. BJU Int. 2007 Mar; 99(3):529-33.
    View in: PubMed
    Score: 0.004
  204. Effects of obesity and height on prostate-specific antigen (PSA) and percentage of free PSA levels among African-American and Caucasian men. Cancer. 2006 Nov 15; 107(10):2361-7.
    View in: PubMed
    Score: 0.004
  205. Sperm banking: use and outcomes in patients treated for testicular cancer. BJU Int. 2007 Jan; 99(1):33-6.
    View in: PubMed
    Score: 0.004
  206. Androgen and anti-androgen treatment modulates androgen receptor activity and DJ-1 stability. Prostate. 2006 Aug 01; 66(11):1177-93.
    View in: PubMed
    Score: 0.004
  207. Patterns of initial transitional cell recurrence in patients after cystectomy. J Urol. 2006 Jun; 175(6):2054-7.
    View in: PubMed
    Score: 0.004
  208. Morbidity and efficacy of genitofemoral nerve grafts with radical retropubic prostatectomy. Urology. 2006 Apr; 67(4):789-92.
    View in: PubMed
    Score: 0.004
  209. Significance of atypical and suspicious small acinar proliferations, and high grade prostatic intraepithelial neoplasia on prostate biopsy: implications for cancer detection and biopsy strategy. J Urol. 2006 Mar; 175(3 Pt 1):929-33; discussion 933.
    View in: PubMed
    Score: 0.004
  210. Robotic assisted laparoscopic radical prostatectomy versus retropubic radical prostatectomy: a prospective assessment of postoperative pain. J Urol. 2005 Sep; 174(3):912-4; discussion 914.
    View in: PubMed
    Score: 0.004
  211. Renal cell carcinoma with renal vein and inferior vena caval involvement: clinicopathological features, surgical techniques and outcomes. J Urol. 2005 Jun; 173(6):1897-902.
    View in: PubMed
    Score: 0.003
  212. Urethral recurrence in patients following orthotopic urinary diversion. J Urol. 2004 Oct; 172(4 Pt 1):1338-41.
    View in: PubMed
    Score: 0.003
  213. Outcomes in patients with pathological carcinoma in situ only disease at radical cystectomy. J Urol. 2004 Sep; 172(3):882-4.
    View in: PubMed
    Score: 0.003
  214. Complications of inguinal and pelvic lymphadenectomy for squamous cell carcinoma of the penis: a contemporary series. J Urol. 2004 Aug; 172(2):494-7.
    View in: PubMed
    Score: 0.003
  215. Adverse prognostic significance of capsular incision with radical retropubic prostatectomy. J Urol. 2004 Jul; 172(1):119-23.
    View in: PubMed
    Score: 0.003
  216. Benefit of radical cystectomy in the elderly patient with significant co-morbidities. Urol Oncol. 2004 May-Jun; 22(3):178-81.
    View in: PubMed
    Score: 0.003
  217. Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies: implications for possible apical sparing surgery. J Urol. 2004 Feb; 171(2 Pt 1):646-51.
    View in: PubMed
    Score: 0.003
  218. Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. J Urol. 2003 Oct; 170(4 Pt 1):1085-7.
    View in: PubMed
    Score: 0.003
  219. Single-center comparison of purely laparoscopic, hand-assisted laparoscopic, and open radical nephrectomy in patients at high anesthetic risk. J Endourol. 2003 Apr; 17(3):161-7.
    View in: PubMed
    Score: 0.003
  220. Partial nephrectomy safely preserves renal function in patients with a solitary kidney. J Urol. 2003 Jan; 169(1):79-81.
    View in: PubMed
    Score: 0.003
  221. Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol. 2003 Jan; 169(1):145-7; discussion 147-8.
    View in: PubMed
    Score: 0.003
  222. Orthotopic neobladder following radical cystectomy in patients with high perioperative risk and co-morbid medical conditions. J Urol. 2002 Dec; 168(6):2454-6.
    View in: PubMed
    Score: 0.003
  223. Preservation of the anterior vaginal wall during female radical cystectomy with orthotopic urinary diversion: technique and results. J Urol. 2002 Oct; 168(4 Pt 1):1442-5.
    View in: PubMed
    Score: 0.003
  224. Causes of increased length of stay following radical cystectomy. Urol Nurs. 2002 Oct; 22(5):319-23, 339.
    View in: PubMed
    Score: 0.003
  225. Analysis of early complications after radical cystectomy: results of a collaborative care pathway. J Urol. 2002 May; 167(5):2012-6.
    View in: PubMed
    Score: 0.003
  226. Routine postoperative intensive care monitoring is not necessary after radical cystectomy. J Urol. 2002 Mar; 167(3):1321-4.
    View in: PubMed
    Score: 0.003
  227. Causes of increased hospital stay after radical cystectomy in a clinical pathway setting. J Urol. 2002 Jan; 167(1):208-11.
    View in: PubMed
    Score: 0.003
  228. Radical cystectomy is safe in elderly patients at high risk. J Urol. 2001 Sep; 166(3):938-41.
    View in: PubMed
    Score: 0.003
  229. Clinical and pathologic findings in hereditary spastic paraparesis with spastin mutation. Neurology. 2000 Jul 12; 55(1):89-94.
    View in: PubMed
    Score: 0.002
  230. [Incidence and clinical significance of false-negative sextant biopsies of the prostate]. Urologe A. 1998 Nov; 37(6):660.
    View in: PubMed
    Score: 0.002
  231. Repeat transrectal ultrasound-guided prostate biopsy: a strategy to improve the reliability of needle biopsy grading in patients with well-differentiated prostate cancer. Urology. 1998 Oct; 52(4):659-62.
    View in: PubMed
    Score: 0.002
  232. Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol. 1998 Apr; 159(4):1247-50.
    View in: PubMed
    Score: 0.002
  233. Radical cystectomy in the octogenarian. J Urol. 1997 Dec; 158(6):2113-7.
    View in: PubMed
    Score: 0.002
  234. Clinical significance of repeat sextant biopsies in prostate cancer patients. Urology. 1997 Mar; 49(3A Suppl):113-8.
    View in: PubMed
    Score: 0.002
  235. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Urology. 1997 Mar; 49(3A Suppl):46-55.
    View in: PubMed
    Score: 0.002
  236. Evaluating neoadjuvant therapy effectiveness on systemic disease: use of a prostatic-specific membrane reverse transcription polymerase chain reaction. Urology. 1997 Mar; 49(3A Suppl):95-101.
    View in: PubMed
    Score: 0.002
  237. Upper tract tumors in patients with primary bladder cancer followed for 15 years. J Urol. 1996 Oct; 156(4):1286-7.
    View in: PubMed
    Score: 0.002
  238. A prospective evaluation of leak point pressure, bladder compliance and clinical status in myelodysplasia patients with tethered spinal cords. J Urol. 1994 Jan; 151(1):177-80; discussion 180-1.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.